Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.
OBJECTIVE
Phosphodiesterase-5 (PDE-5) inhibitors have an established role in the treatment of erectile dysfunction, but there is increasing evidence that these drugs are effective also for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia (BPH). The mechanism of action of PDE-5 inhibitors in the prostate, however, is poorly understood. It is conceivable that these drugs act by reducing the smooth muscle tone of the organ, but this effect could produce vascular changes as well. The aim of this study was to investigate whether administration of Tadalafil, a PDE-5 inhibitor, in patients with BPH produces haemodynamic changes in the prostate that can be assessed using contrast-enhanced US (CEUS).


METHODS
Twelve consecutive patients with BPH underwent transrectal CEUS before and 90 min after administration of 20 mg Tadalafil. CEUS was performed during bolus injection of SonoVue (4.8 ml) using a nondestructive US mode. The same scan plane, imaging parameters and technique were used before and after Tadalafil administration. Digital clips were recorded and processed using dedicated software (QontraXt v.3.60. Signal intensity (SI) changes in a region of interest (ROI) encompassing the entire prostate were fitted to a gammavariate curve. Changes in enhancement peak, time to peak (TTP), sharpness of the bolus transit and area under the curve (AUC) were considered for further analysis.


RESULTS
After Tadalafil administration, the enhancement peak and AUC increased significantly (p<0.01), reflecting changes in prostate vascularity. TTP and sharpness did not change significantly.


CONCLUSIONS
In patients with BPH, vascular changes are observed in the prostate after Tadalafil administration, which can be detected with CEUS.
Bertolotto
M
M
UCO di Radiologia, Università di Trieste, Ospedale di Cattinara, Trieste, Italy. bertolot@units.it
Trincia
E
E
Zappetti
R
R
Bernich
R
R
Savoca
G
G
Cova
M A
MA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002243:Carbolines / Q000008:administration & dosage / Q000627:therapeutic use*; D003287:Contrast Media; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D036502:Infusions, Intralesional; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011467:Prostate / Q000098:blood supply / Q000000981:diagnostic imaging*; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D000068581:Tadalafil; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D002243:Carbolines; D003287:Contrast Media; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil
Int J Impot Res. 2007 Nov-Dec;19(6):533-43
17625575
Pharmacol Rev. 2000 Sep;52(3):375-414
10977868
J Urol. 2001 Dec;166(6):2484-90
11696815
Invest Radiol. 2006 Jan;41(1):15-21
16355035
Eur Urol. 2006 Dec;50(6):1316-22
16831513
World J Urol. 2002 Apr;19(6):436-42
12022712
Urology. 2002 Sep;60(2 Suppl 2):4-11
12414329
Neurourol Urodyn. 2007 Oct;26(6 Suppl):928-33
17806124
J Am Coll Cardiol. 2001 Mar 15;37(4):1135-40
11263620
Curr Pharm Des. 2006;12(27):3439-57
17017938
Eur Urol. 2003 Feb;43(2):124-31
12565769
AJR Am J Roentgenol. 2007 Apr;188(4):977-83
17377033
Eur J Radiol. 2007 Nov;64(2):231-8
17881175
Prostate. 2002 Apr 1;51(1):50-8
11920958
Circulation. 1998 Feb 10;97(5):473-83
9490243
Radiology. 2002 Feb;222(2):460-7
11818614
Gene. 1998 Aug 17;216(1):139-47
9714779
Med Hypotheses. 2007;69(1):25-6
17300876
J Urol. 2007 Apr;177(4):1401-7
17382741
BJU Int. 2006 Dec;98(6):1259-63
16956354
Urol Res. 1996;24(3):123-8
8839478
Eur Urol. 2007 Aug;52(2):495-501
17329019
Ultrasound Med Biol. 2001 Aug;27(8):1059-64
11527592
J Urol. 2007 Aug;178(2):464-8; discussion 468
17561137
Biochem Biophys Res Commun. 1998 Jun 18;247(2):249-54
9642111
Circ Res. 2003 Aug 22;93(4):280-91
12933699